Ann Clin Case Rep | Volume 3, Issue 1 | Case Report | Open Access

Somatostatin Receptor Scintigraphy with 111In- Pentetreotide for Detection of Atypical Metastatic Localization of a Midgut Neuroendocrine Tumor: A Case Study

Lyonel Belia1, Eddy Glaude1, Caroline Faes1, Thibault Michelin1, Mona Hedreville1, Mathon Grégory1, Ulises Jáuregui-Haza2 and Fritz-Line Vélayoudom-Céphise1,3*

1Department of Endocrinologie, University Hospital of Pointe-à-Pitre, Cuba
2Department of Endocrinologie, University of Havana, Cuba
3Department of Endocrinologie, University of the French West Indies, Cuba

*Correspondance to: Fritz-Line VĂ©layoudom-CĂ©phise 

Fulltext PDF

Abstract

A 49-year-old man was referred to the University Hospital of Pointe-à-Pitre for abdominal pains. He underwent a midgut neuroendocrine tumor (NET) resection 8 years ago. The computed tomography revealed multiple liver metastases. 111In-pentetreotide, SPECT/CT identified liver metastases and a suspect cardiac uptake. A cardiac magnetic resonance imaging confirmed a thickening of the bottom wall of the heart, measuring 24 mm compatible with a cardiac metastasis of the NET.111In-Pentetreotide SPECT/CT remains a good functional imaging compared to conventional somatostatin receptor scintigraphy to precise anatomical localization of NET metastases and could help to select the best morphological imaging to complete the staging of metastatic NET. The delayed detection of the cardiac metastasis did not allow setting up an effective management and the patient dead due to an uncommon hepatic metastasis compression of the heart.

Keywords:

Neuroendocrine tumor; Somatostatin receptor scintigraphy; 111In-pentetreotide

Citation:

Belia L, Glaude L, Faes C, Michelin T, Hedreville M, Grégory M, et al. Somatostatin Receptor Scintigraphy with 111In-Pentetreotide for Detection of Atypical Metastatic Localization of a Midgut Neuroendocrine Tumor: A Case Study. Ann Clin Case Rep. 2018; 3: 1488.

Subscribe to Our Newsletter